

**ZINC SUPPLEMENTATION AND COVID-19 PANDEMIC: A WAY TO OVERCOME  
THE COVID 19 PANDEMIC IN THIRD WORLD COUNTRIES**\*<sup>1</sup>Waleed Zahoor Bandey and <sup>2</sup>Wasim Farooq<sup>1</sup>Medical Coordinator, Covid Clinic, SKIMS, India.<sup>2</sup>Junior Resident, GMC Doda, India.**\*Corresponding Author: Waleed Zahoor Bandey**  
Medical Coordinator, Covid Clinic, SKIMS, India.

Article Received on 30/05/2021

Article Revised on 21/06/2021

Article Accepted on 11/07/2021

**ABSTRACT**

Coronavirus disease-19 (COVID-19)-induced severe acute respiratory syndrome is a global pandemic. As a preventive measure, human movement is restricted in most of the world. The Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), along with the World Health Organization (WHO) have laid out some therapeutic guidelines for the infected patients. However, other than handwashing and vigilance surrounding commonly encountered oronasal symptoms and fever, no universally available prophylactic measure has yet been established. In a pandemic, the accessibility of a prophylactic biologically active substance is crucial. Ideally, it would be something readily available at a low price to a larger percentage of the population with minimal risk. Studies have demonstrated that zinc may reduce viral replication and increase immune responses. While consuming zinc (within the recommended upper safety limits), as a prophylactic might provide an additional shield against the initiation and progression of COVID-19.

**KEYWORDS:** COVID 19, Zinc, immunity.**Zinc: An antiviral nutrient**

SARS-CoV-2, the novel virus that causes COVID-19 infection, is estimated to have infected over 109 million people worldwide causing more than 2.4 million deaths as of February 16, 2021 (data collected from Coronavirus resource center of Johns Hopkins University, Maryland, U.S.). With heterogeneous clinical presentations, it is a global priority to encourage collaborative efforts toward developing meaningful uniform therapeutic strategies to treat and reduce disease mortality. One strategy may include zinc supplementation. The zinc compound has been speculated to reduce influenza viral infection through its antiviral effects in humans. Using cultured chorion cells prepared from human fetal membranes, a reduced replication of the influenza virus was noted with a zinc ionophore (pyrrolidine dithiocarbamate)

Zinc oxide nanoparticles exert antiviral effects against the H1N1 influenza virus infection. In a related study, polyethylene glycol-coated zinc oxide nanoparticles inhibited more than 90% of H1N1 influenza virus loads. Zinc has also been shown to inhibit the replication of severe acute respiratory syndrome (SARS) coronavirus by cell culture studies on Vero- E6 cells. Using both zinc ions and zinc-ionophore (pyrithione), the replication of SARS coronavirus was reduced when intracellular concentration of zinc was high. The zinc-mediated inactivation of the RNA-dependent RNA polymerase

(RdRp; core replication enzyme) is a possible mechanism of inhibition of SARS coronavirus replication. Of relevance, replication of SARS-CoV-2 also needs two essential enzymes, RdRp and 3C-like proteinase (3CLpro). The zinc-binding sites were shown to be conserved in RdRp and 3CLpro by molecular modeling. Though exact mechanisms are not yet defined, zinc-binding can reduce the enzymatic activities of 3CLpro and RdRp to inhibit viral replication. In vitro studies have claimed that low zinc levels favor viral multiplication in SARS CoV- 2 infected cells. Similarly, zinc could markedly inhibit the replication potential of the respiratory syncytial virus.

Investigators had shown an 800-fold reduction in the respiratory syncytial virus when 10 IM concentration of zinc was present during preincubation, adsorption, penetration, and egress. In the clinical scenario, zinc supplementation resulted in a marked reduction in pneumonia prevalence in children. Hepatitis C virus (HCV) replication has also been suppressed by zinc, and zinc supplementation has enhanced the response of antiviral therapy for HCV-induced hepatitis patients. The exact underlying mechanism of zinc-induced antiviral response is not well understood; however, it has been demonstrated that zinc has the potential to inhibit viral binding to the mucosal cells, and eventual replication, possibly by generating antiviral interferon (IFN)- $\alpha$  and

IFN- $\gamma$ . In another study, zinc supplementation taken for 24 weeks, enhanced the response to INF- $\alpha$  therapy in patients with intractable chronic hepatitis C, as clinically determined by the serum level of aminotransferase and the presence of RNA for HCV. SARS-CoV-2 can bind to the cell surface angiotensin converting enzyme 2 (ACE2) through its spike proteins for entering into the cells to initiate viral replication and transcription. Earlier studies have shown that ACE-2 expression is regulated by Sirtuin 1 (SIRT1), and zinc can reduce SIRT-1-mediated ACE2 expression. Experimental studies conducted on human lung cell lines, and treated with zinc in combination with triclabendazole (anthelmintic drug) or emetine (antiprotozoal drug), have shown to suppress ACE2 expression without producing cytotoxicity. Monotherapy with triclabendazole or emetine failed to suppress ACE2 levels, suggesting the importance of zinc on the expression of ACE2.

In this pandemic, chloroquine has been used to treat COVID-19 infection, with some early data suggestive of therapeutic potentials. Although there are also studies that reported to have no benefit for using chloroquine on COVID-19 patients and documented increased risk of cardiotoxicity. Notably, chloroquine is an ionophore for zinc and could increase the cellular entry of zinc. Additionally, intracellular antiviral effects of zinc might be partly related to the chloroquine-induced beneficial effects documented in COVID-19 patients. In a recent clinical observation, zinc sulfate, in combination with hydroxychloroquine and azithromycin, has shown to provide better therapeutic benefits to the COVID-19 infected patients than the patients who received hydroxychloroquine and azithromycin, without zinc; an increased frequency of hospital discharge and reduced mortality are documented in zinc sulfate added-COVID-19 patients. It needs to mention that hydroxychloroquine's potential utility to treat COVID-19 patients is debated, particularly the side effects of this drug beyond the acceptable range. Additional controlled studies will also be required to gain better insight into the role and applications of zinc in COVID-19 infection. The rationale for using azithromycin, an antibiotic, against a viral infection was not clearly explained in the aforementioned study. Recent *in vitro* studies on human airway cell lines have shown that zinc and azithromycin can suppress the expression of ACE2, and the investigators have speculated the potential prophylactic and therapeutic value of this combination for COVID-19 patients. Exacerbation of antimicrobial resistance appears to be another casualty of the COVID-19 pandemic, and implementation of antimicrobial stewardship to reduce antimicrobial drug resistance in this pandemic should be a medical priority.

#### **Zinc: an immune-boosting nutrient**

A serum zinc level of 80–130  $\mu\text{g/dl}$  is considered as a normal range, and  $<70 \mu\text{g/dl}$  is regarded as clinical zinc deficiency. Impaired zinc homeostasis adversely affects immune cells by multiple mechanisms that result in the

abnormal formation of lymphocytes, impaired intercellular cytokine communication, and diminished phagocytosis that cause an inadequate host defense. Improved zinc intake may also reduce the risk of bacterial pneumonia co-infection by improving ciliary length and movement that affects viral particle removal and improves mucociliary clearance. There are many ways to supplement zinc through usual food consumption. Meat (lamb, beef, and chicken) and seafood (oysters, and lobster) are zinc-containing food. In addition, black sesame, soy foods, mushrooms, lentils, celery, legumes, nuts, almonds, and sunflower seeds are good sources of zinc. Zinc can also influence the functionality of several immune cells, and an inadequate zinc microenvironment can impair host-defense systems, thus increasing the susceptibility to various microorganisms. *In vitro* studies have shown a higher rate of mouse CD4 + CD8 + thymocyte death by apoptosis in those with low zinc concentrations, while apoptosis was shown to be reduced by adding zinc. In a study of human children, zinc supplementation has been shown to provide T-cell-mediated immunity by increasing the numbers of CD4 + CD8 + cells in peripheral blood. By contrast, zinc deficiency has been shown to impair B-cell development, with low IgG production, leading to higher rates of infection and subsequent mortality. Experimentally induced maternal zinc deficiency caused a lower level of antibody generation in the offspring, while zinc supplementation could restore the impaired antibody-mediated responses. Although the zinc supplementation can increase CD3 + CD4 + cells in the peripheral blood, to better understand T cell-mediated immunity, potential effects of zinc on T cell subsets, including the balance between regulatory T (Treg) cells and T helper type 17 (Th17), are needed. Of relevance, Treg cells can reduce or resolve inflammation, while Th17 cells can promote inflammation in various human diseases with immune dysregulation. Studies have shown that zinc deficiency can drive Th17 polarization and promote the loss of Treg cell function. More importantly, zinc supplementation can suppress Th17 cell development to provide an additional shield against the infection.

Cytotoxic CD8 + cells can kill virally infected cells, and experimental studies have shown that a zinc-deficient diet resulted in reduced population of CD8 + cells, thereby contributing to the exacerbation of the inflammatory responses. Of clinical importance, a low numbers of lymphocyte, including CD8 + cells are shown to be associated with poor prognosis of COVID-19 patients, and increasing lymphocyte counts.

#### **Zinc: effects on COVID-19 patients**

In a recently concluded Conference on Coronavirus Disease of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Dr. Güerri-Fernández and colleagues presented the retrospective analysis data on the impact of zinc on the mortality of COVID-19 patients among the hospital

admitted patients in Spain. Out of 249 studied patients, there was 8% (21 patients) mortality.

The investigators found a significantly lower plasma level of zinc in COVID-19 patients who died (43 lg/dl) than the patients who survived (63.1 lg/dl). After adjusting different variables, the investigators showed each unit increase of plasma zinc at the time of hospital admission resulted in a 7% reduced risk of in-hospital mortality. Also, less than 50 lg/dl of a plasma zinc level at the hospital admission was associated with a 2.3-fold increased risk of in hospital deaths as compared to the patients with a plasma zinc level of 50 lg/dl or higher, suggesting the importance of maintaining adequate zinc balance. In a similar line of study, serum zinc level was found to be relatively low in samples collected from COVID-19 patients compared to the healthy counterparts. The average serum zinc level was remarkably low in the samples collected from the non-surviving COVID-19 patients (n = 6) as compared to the surviving COVID-19 patients (n = 29). In another uncontrolled case series study with COVID-19 patients, a high dose of oral zinc salt resulted in clinical recovery, improved oxygenation, and less shortness of breath among those patients.

A study conducted in Japan on 62 patients with COVID-19 showed a close association between low serum zinc level and severity of the disease. The investigators also found serum zinc level as a predictive factor for a critical illness of patients with COVID-19. In a different study, the fasting zinc level in blood in patients with COVID-19 (n = 47) was significantly lower than the healthy controls (n = 45). The median zinc level in patients with COVID-19 was 74.5 lg/dl, while in the control group, the level was 105.8 lg/dl. The zinc-deficient COVID-19 patients were found to develop more complications, along with extended hospital stay and higher mortality. In a trial conducted on COVID-19 patients (n = 62), treated with combination therapy of Nitazoxanide, Ribavirin, Ivermectin and zinc, showed a more rapid nasopharyngeal clearance of SARS-CoV-2 as compared to the patients (n = 51) who received symptomatic treatment. In a multicenter cohort study on 3473 hospitalized COVID-19 patients (in New York, U.S.), treatment with zinc and an ionophore resulted in a 24% reduced risk of 'in-hospital' mortality; it was an observational study, and zinc sulfate (220 mg) was given orally, once or twice daily for four days or until discharge. As a zinc ionophore, hydroxychloroquine (400 mg twice daily for one day then 200 mg twice daily for four days) was used in patients whose oxygen saturation was <94% on room air, and whose QTc interval was <500 ms. Among the zinc and ionophore treated group of 1005 hospitalized COVID-19 patients, 121 patients (12%) died, while among 2467 patients who did not receive zinc and ionophore, 424 patients (17%) died. However, it needs to be mentioned that not all the studies found an association between zinc consumption and disease severity in COVID-19 patients. In a retrospective analysis of 242 (Zinc-treated group: n = 196; Control

group: n = 46) hospitalized patients with COVID-19, treated with zinc sulfate at a total daily dose of 440 mg (100 mg elemental zinc) showed neither additional benefit nor harmful health effects; since overall zinc status of the patients was not analyzed, no definitive conclusion could be drawn from this study; also the retrospective nature of the study prevented in adjusting the uniform dose and duration of the study.

It is important to note that physicians' recommendations should be sought before consuming zinc to minimize potential adverse effects. Acute exposure to high doses of zinc may induce gastrointestinal tract disorders, including nausea, vomiting, loss of appetite, epigastric pain, diarrhea, along with headache and fatigue. Chronic zinc toxicity may include lethargy, copper deficiency, and severe iron deficiency anemia. Excessive zinc levels are cytotoxic and shown to induce higher mortality in experimental studies. The risk of developing adverse effects may limit the tolerability and long-term use of zinc.

## CONCLUSION

The holistic approach of maintaining an adequate nutritional balance with healthy eating habits and keeping an active lifestyle are likely to reduce the disease burden of the COVID-19 pandemic. Without the mass availability of effective vaccines or specific drugs to treat or control COVID-19 infection, social distancing and home isolation are the most recommended measures employed to minimize the spread of COVID-19-associated infection. However, consuming zinc has the potential to provide an additional shield against the illness, possibly by reducing viral load and enhancing the immunity of the COVID-19 patients. The elevated intracellular concentration of zinc could inactivate the RNA-dependent RNA polymerase, the core viral replication enzyme, which could reduce viral replication and might have the potential to minimize the disease burden. Further studies will determine the relevance of experimental studies with zinc on human viral diseases. Of relevance, 40 mg of zinc per day is considered as the tolerable upper intake level and is unlikely to induce toxicity. Whether this same level of zinc intake can provide added protection against COVID-19 infection, perhaps by enhancing the host resistance, is an area that needs additional studies; the results of the ongoing clinical trials around the world will shed further light. Another added benefit of zinc is that it is generally considered very safe to consume without harmful effects, even when consumed well above the daily recommended dietary intake. The potential benefits of taking zinc in an effort to stave off COVID-19 infection will require carefully designed research studies and clinical trials to be universally recommended and would need to be a prospective, randomized placebo-controlled trial. Of clinical significance, zinc deficiency has a deleterious association with severely ill patients beyond COVID-19. For instance, a South Korean study has reported that severely ill patients, who died after an intensive care unit

(ICU) transfer, showed hypozincemia. Even after treatment, the serum level of zinc did not change in these patients.

The double-blinded randomized controlled trials continue to be the gold standard of clinical studies. ClinicalTrials.gov and the WHO's International Clinical Trials Registry Platform (WHO ICTRP) have enlisted around 50 clinical trials to test the effects of various doses of zinc on the initiation and the progression of COVID-19 patients. Ongoing clinical trials on COVID-19 patients, either with zinc or with zinc and ionophores (quercetin or epigallocatechin gallate) are likely to extract additional information on its clinical utility. The results of these ongoing studies in different parts of the world, particularly double-blinded randomized controlled trials, would provide information on the therapeutic value of zinc, either as a prophylactic or as an adjuvant therapy to minimize the disease burdens of COVID-19 patients. Available clinical studies with zinc supplementation on COVID-19 patients, although sparse, suggest promising prospects. Finally, the success of the ongoing COVID-19 vaccination program may be partly dependent on zinc sufficiency, and that low zinc availability may affect the vaccination responses.

developing countries: pooled analysis of randomized controlled trials. Zinc Investigators' Collaborative Group. *J Pediatr*, 1999; 135: 689–97.

#### Further Reading

1. Eby GA. Zinc ion availability—the determinant of efficacy in zinc lozenge treatment of common colds. *J Antimicrob Chemother*, 1997; 40: 483–93.
2. Hemila H. Common cold treatment using zinc. *JAMA*, 2015; 314: 730.
3. Read SA, Obeid S, Ahlenstiel C, Ahlenstiel G. The role of zinc in antiviral immunity. *Adv Nutr*, 2019; 10: 696–710.
4. Eby 3rd GA. Zinc lozenges as cure for the common cold—a review and hypothesis. *Med Hypotheses*, 2010; 74: 482–92.
5. Uchida N, Ohshima K, Bessho T, Yuan B, Yamakawa T. Effect of antioxidants on apoptosis induced by influenza virus infection: inhibition of viral gene replication and transcription with pyrrolidine dithiocarbamate. *Antiviral Res*, 2002; 56: 207–17.
6. Ghaffari H, Tavakoli A, Moradi A, Tabarraei A, Bokharaei-Salim F, Zahmatkeshan M, et al. Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine. *J Biomed Sci.*, 2019; 26: 70.
7. Pormohammad A, Monych NK, Turner RJ. Zinc and SARS-CoV-2: a molecular modeling study of Zn interactions with RNA-dependent RNA-polymerase and 3C-like proteinase enzymes. *Int J Mol Med*, 2021; 47: 326–34.
8. Suara RO, Crowe Jr JE. Effect of zinc salts on respiratory syncytial virus replication. *Antimicrob Agents Chemother*, 2004; 48: 783–90.
9. Bhutta ZA, Black RE, Brown KH, Gardner JM, Gore S, Hidayat A, et al. Prevention of diarrhea and pneumonia by zinc supplementation in children in